Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$27.80
-$0.11(-0.77%)
At close: 4:00 PM EST
$27.80
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$11.51 - $29.75
Previous CloseN/A
Volume35.38K
Average Volume (3M)743.90K
Market Cap
$1.70B
Enterprise Value$1.48B
Total Cash (Recent Filing)$364.73M
Total Debt (Recent Filing)$17.04M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Jul 30, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding73,023,060
10 Day Avg. Volume685,721
30 Day Avg. Volume743,905
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue18.15
Enterprise Value/Gross Profit19.23
Enterprise Value/Ebitda-15.64
Forecast
1Y Price Target
$39.00Price Target Upside40.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.53
Revenue Forecast (FY)$318.86M
Bulls Say, Bears Say
Bulls Say
Proprietary ADC And Pan‑RAS PlatformZymeworks’ DAR‑8 ADC formats and pan‑RAS preclinical program produced multiple candidate molecules with favorable xenograft efficacy and NHP tolerability. A scalable ADC platform provides durable optionality across targets, enabling multiple clinic-ready assets and long‑term pipeline value beyond any single program.
ZW191 Strong Phase I Clinical SignalsCompelling single‑agent activity in heavily pretreated ovarian and endometrial cohorts materially de‑risks the internal ADC program. Durable response signals and a favorable tolerability profile improve the odds of late‑stage development, commercial optionality, and partnership leverage over multiple development cycles.
Stronger Liquidity Plus Milestone RunwayA larger cash balance combined with significant anticipated approval‑linked milestones supports funding for R&D and potential commercialization into 2028 under management's plan. This improves near‑term financial flexibility and reduces immediate dilution pressure, provided milestone realizations occur as projected.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow signifies an underlying cash‑burn model. Without recurring revenue growth or milestone receipts, the company will face persistent funding needs that can force cuts, dilution, or reliance on non‑recurring transactions, stressing long‑term financial resilience.
Revenue Collapse And Partner DependenceA ~91% YoY revenue drop driven by lost nonrecurring milestones highlights that top‑line is volatile and heavily partner‑dependent. This undermines margin sustainability and makes the company’s runway and growth contingent on external approvals and milestone timing outside management’s direct control.
Pipeline Timing And Execution RiskProgram delays and the fact that key assets (e.g., pan‑RAS ADCs) remain preclinical increase time‑to‑revenue and require IND‑enabling CMC work or partnerships. Protracted development timelines raise funding sensitivity and heighten the chance that milestones and royalties arrive later than expected.
Zymeworks News
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $11.51 and its highest was $29.75 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.70B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on May 07, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.297 by -$0.293.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.37.
How many shares outstanding does Zymeworks have?
Zymeworks has 73,023,060 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.297. Following the earnings report the stock price went down -10.188%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.00 (40.29% Upside)
$39.00 (40.29% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 581.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.28%
12-Months-Change
Fundamentals
Return on Equity
-37.79%
Trailing 12-Months
Asset Growth
12.38%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$39.00
▲(40.29% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
1.27% Insiders
8.47% Mutual Funds
61.91% Other Institutional Investors
17.60% Public Companies and
Individual Investors